ПАЛЬКА Конрад (PL),ГЕБИЦКИЙ Ежи (PL),ВЕЧОРКОВСКА Мажена (PL),ЦЕФАЛИ Иудженио А. (US)
申请号：
RU2019104343
公开号：
RU2019104343A
申请日:
2017.07.16
申请国别(地区):
RU
年份:
2020
代理人:
摘要：
The use of 1-MNA or a pharmaceutically acceptable salt thereof for reducing the risk of cardiovascular disease in a subject with a blood or serum CRP level of less than 10 mg/L. The disclosure also discloses the use of 1-MNA or a pharmaceutically acceptable salt thereof in the amount effective for reducing the blood or serum CRP level for the treatment of diseases such as rheumatoid arthritis, colon cancer, breast cancer, lung cancer, infection, inflammatory bowel disease, lupus erythematosus, pneumococcal pneumonia, rheumatic fever, tuberculosis, renal failure, amyotrophic lateral sclerosis, or a combination thereof.
